STRO
Sutro Biopharma, Inc.
There isn't enough reported data to score STRO yet.
STRO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
STRO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
STRO PE Valuation
STRO has no meaningful PE right now: it lost money over the past year.
STRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect STRO's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
STRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$25.50 | -$9.40 |
| Q2 2025 | -$24.70 | -$6.40 |
| Q1 2025 | -$29.20 | -$10.40 |
| Q4 2024 | -$29.60 | -$11.80 |
| Q3 2024 | -$16.10 | +$12.80 |
| Q2 2024 | -$18.30 | +$6.20 |
| Q1 2024 | -$18.80 | +$4.80 |
| Q4 2023 | -$17.80 | +$5.70 |
STRO lost $25.50 per share over the past year, a bigger loss than the year before.
STRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.1M | -6.1% |
| Q2 2026 | $9.8M | -85% |
| Q1 2026 | $14.5M | -17% |
| Q4 2025 | $11.6M | -21% |
| Q3 2025 | $9.7M | +14% |
| Q2 2025 | $63.7M | +148% |
| Q1 2025 | $17.4M | +34% |
| Q4 2024 | $14.8M | -87% |
STRO's revenue has slid since its 2023 peak: $9M last quarter, down 6.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -241% | +259 points |
| Q2 2026 | -304% | -299 points |
| Q1 2026 | -204% | +190 points |
| Q4 2025 | -327% | +114 points |
| Q3 2025 | -500% | +297 points |
| Q2 2025 | -5.3% | +184 points |
| Q1 2025 | -394% | +41 points |
| Q4 2024 | -441% | -479 points |
STRO's operating margin was −241% last quarter, up 259 points from the same quarter a year ago.
STRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.5M | +$15.7M |
| Q2 2026 | -$38.3M | +$6.4M |
| Q1 2026 | -$42.3M | +$25.6M |
| Q4 2025 | -$26.4M | +$45.3M |
| Q3 2025 | -$38.2M | +$26.3M |
| Q2 2025 | -$44.7M | -573% |
| Q1 2025 | -$67.9M | -$3.1M |
| Q4 2024 | -$71.7M | -610% |
STRO has burned cash in almost every quarter: −$129M over the past year, against −$223M the year before.
STRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +12.2K shares |
| 1 year | +96% | +8.1M shares |
| 3 years | +175% | +10.5M shares |
| 5 years | +260% | +12M shares |
| Available history | +622% | +14.3M shares |
STRO has 17M diluted shares, up 96% from a year ago.
STRO Net Leverage
STRO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
STRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 7.3 | Oversold |
STRO's weekly RSI is 30 (neutral) and its Stochastic is 7 (oversold).
STRO PE vs Healthcare Sector
STRO has no meaningful PE right now: it lost money over the past year.
STRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 19% below |
| 20 week MA | $18.2 | 47% below |
| 50 week MA | $20.7 | 54% below |
| 100 week MA | $15.8 | 39% below |
| 200 week MA | $29.0 | 67% below |
STRO is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
STRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $109.8 | $220.8 | +101% |
| 2021 | $220.8 | $142.5 | -35% |
| 2022 | $142.5 | $68.7 | -52% |
| 2023 | $68.7 | $42.9 | -38% |
| 2024 | $42.9 | $18.9 | -56% |
| 2025 | $18.9 | $11.5 | -39% |
| 2026 YTD | $11.5 | $9.59 | -17% |
STRO has finished five years in a row lower, and it's down 17% so far in 2026.